Quantcast
Channel: Endpoints News
Viewing all articles
Browse latest Browse all 6022

Bristol Myers Squibb’s Reblozyl fails Phase 3 in anemia; Sanofi, Blueprint deal closes 

$
0
0
Plus, news about DiaMedica Therapeutics, Cantargia and Quetzal Therapeutics: Bristol Myers Squibb suffers late-stage miss in anemia: Patients with myelofibrosis-associated anemia taking Reblozyl were no more able than those on placebo to go three months ...

Viewing all articles
Browse latest Browse all 6022

Trending Articles